2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N7143R
    Monobutyl phthalate (Standard) 131-70-4 99.86%
    Monobutyl phthalate (Standard) is the analytical standard of Monobutyl phthalate. This product is intended for research and analytical applications. Monobutyl phthalate, a major metabolite of dibutyl phthalate (DBP), possesses antiandrogenic effects. Monobutyl phthalate is an embryotoxicant.
    Monobutyl phthalate (Standard)
  • HY-N9516A
    Taurodehydrocholic acid sodium 57011-24-2 99.87%
    Taurodehydrocholic acid sodium is a biliary cholesterol secretion activator. Taurodehydrocholic acid sodium significantly increases the expression of Abcg5 and decreases the expression of abc8. Taurodehydrocholic acid sodium can be used in the study of cholesterol metabolism.
    Taurodehydrocholic acid sodium
  • HY-P0262A
    Galantide TFA 98.77%
    Galantide TFA is a reversible and non-specific galanin (GAL) receptor antagonist. Galantide TFA dose-dependently shows antagonism to galanin-induced K+ conductance with an IC50 value of 4 nM. Galantide TFA can be used for the research of neurological disease and hormone metabolism research.
    Galantide TFA
  • HY-P10377
    GUB03385
    GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC50: 0.4 nM) and NPFF2R (partial agonist, EC50: 20 nM). GUB03385 has anti-obesity effect.
    GUB03385
  • HY-P11212
    Ac-RHKK(Ac)-AMC 1193634-36-4 99.68%
    Ac-RHKK(Ac)-AMC (Compound S1) is a fluorescent substrate for SITR6, that is based on p53 sequence. Ac-RHKK(Ac)-AMC mimics H3K56 deacetylation site and significantly increases the deacetylation signal with low signal-to-background ratio. Ac-RHKK(Ac)-AMC can be used for ageing and cancers research.
    Ac-RHKK(Ac)-AMC
  • HY-P11213
    Ac-RYQK(Ac)-AMC 99.55%
    Ac-RYQK(Ac)-AMC (Compound S5) is a fluorescent substrate for SITR6, that is based on the H3 sequence. Ac-RYQK(Ac)-AMC mimics H3K56 deacetylation site and significantly increases the deacetylation signal with superior signal-to-background ratio. Ac-RYQK(Ac)-AMC can be used for ageing and cancers research.
    Ac-RYQK(Ac)-AMC
  • HY-P11320
    Davalintide 863919-85-1 98.04%
    Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC50 = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC50 = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes.
    Davalintide
  • HY-P1712A
    Arthrofactin TFA
    Arthrofactin (TFA) is an effective lipopeptide biosurfactant in Pseudomonas sp. MIS38. Arthrofactin (TFA) production is associated with multiple ATP dependent active transporter systems.
    Arthrofactin TFA
  • HY-P2149A
    Concanavalin A (agarose) 11028-71-0
    Concanavalin A (agarose) is composed of Concanavalin A (HY-P2149) conjugated with agarose. Concanavalin A (ConA) is a selective competitive binder targeting the specific carbohydrate structures of glucose and mannose, inducing mitosis, and exhibiting certain cytotoxicity, hepatotoxicity, and teratogenicity. Concanav in A (agarose) can be used for in vivo blood glucose monitoring in diabetes, and for "fishing out" specific glycoproteins or removing sugar impurities from complex samples.
    Concanavalin A (agarose)
  • HY-P2869C
    β1-3,4 Galactosidase 9031-11-2
    β1-3,4 Galactosidase is a highly specific exoglycosidase that catalyzes the hydrolysis of terminal β1-3 and β1-4 linked galactose residues from oligosaccharides.
    β1-3,4 Galactosidase
  • HY-P5077A
    Guanylin (mouse, rat) TFA
    Guanylin (mouse, rat) TFA, a petide, is composed of 15 amino acids. Guanylin (mouse, rat) TFA is an activator of intestinal guanylate cyclase. Guanylin (mouse, rat) TFA can be used for the research of diarrhea.
    Guanylin (mouse, rat) TFA
  • HY-P5815A
    GLP-1 (1-36) amide (human, rat) TFA 98.02%
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells.
    GLP-1 (1-36) amide (human, rat) TFA
  • HY-U00346
    TS-021 free base 625110-37-4 98.84%
    DPP-IV-IN-1 is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV), a highly specific serine protease, with an IC50 of 4.6 nM.
    TS-021 free base
  • HY-101337A
    Imiloxan hydrochloride 81167-22-8 98.47%
    Imiloxan (RS 21361) hydrochloride is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan hydrochloride produces a dose-related reversal of Guanoxabenz (HY-U00123)-induced maximal mydriasis in male rats. Imiloxan hydrochloride has the potential for acute kidney injury research.
    Imiloxan hydrochloride
  • HY-103320B
    (1R,2R)-Calhex 231 hydrochloride 98.45%
    (1R,2R)-Calhex 231 hydrochloride is the isomer of Calhex 231 hydrochloride (HY-103320A), and can be used as an experimental control. Calhex 231 hydrochloride is a CaSR inhibitor via negative allosteric modulation. Calhex 231 hydrochloride blocks Ca2+-induced accumulation of [3H]inositol phosphate with an IC50 of 0.39 μM in HEK293 cells. Calhex 231 hydrochloride has the potential for diabetic cardiomyopathy (DCM) treatment.
    (1R,2R)-Calhex 231 hydrochloride
  • HY-106019C
    Liarozole dihydrochloride 1883548-96-6 ≥99.0%
    Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties.
    Liarozole dihydrochloride
  • HY-107855S
    DL-Mevalonolactone-d7 347840-19-1 99.27%
    DL-Mevalonolactone-d7 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (?Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling.
    DL-Mevalonolactone-d7
  • HY-113005A
    Glutarylcarnitine lithium
    Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
    Glutarylcarnitine lithium
  • HY-113005S
    Glutarylcarnitine-d9 chloride 98.09%
    Glutarylcarnitine-d9 (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
    Glutarylcarnitine-d9 chloride
  • HY-113147B
    L-Palmitoylcarnitine TFA 98.0%
    L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2.
    L-Palmitoylcarnitine TFA
Cat. No. Product Name / Synonyms Application Reactivity